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See Article, pages 182–189The prevalence of non-alcoholic fatty liver disease (NAFLD) in the
community is probably rising, driven by the epidemics of obesity
and diabetes. A provocative study on obesity prevalence in the
U.S. suggested that, given the trend observed between 1970
and 2004, all American adults would become overweight or
obese by 2048, with differences between genders and ethnic
ancestry [1]. Similar data exist for the prevalence of type 2 diabe-
tes, which is now well above a 10% prevalence rate in several
countries, with an estimated total of 382 million cases through-
out the world and a prospective rise to 592 million cases in the
next 25 years [2]. From the early description of NAFLD, we know
that the disease is intimately connected with obesity, diabetes
and the metabolic syndrome, therefore it is not surprising that
NAFLD is among the top three causes of liver transplantation.
Considering the rapid advances in antiviral therapy, it is expected
to become the most common indication in the near future. A cor-
rect identiﬁcation of incident cases may help to determine addi-
tional risk factors and program therapeutic interventions.
Only a few studies have been available so far on fatty liver or
NAFLD incidence (Table 1). The usual method to diagnose NAFLD
has been ultrasonography, sometimes coupled with raised liver
enzymes [3–10]. We all know that this method is crude, impre-
cise, highly insensitive and operator-dependent and cannot pro-
vide quantitative data. Overall, data are remarkably different in
relation to study population, age, gender and comorbidities (in
particular, to the presence/absence of obesity and the method
of ascertainment). In the present issue of the Journal, Wong
et al. present their analysis of NAFLD incidence based on paired
proton-magnetic resonance spectroscopy (MRS) in a commu-
nity-based Hong-Kong cohort, where also the parameters of met-
abolic syndrome were recorded [11]. In 565 cases without
evidence of NAFLD at baseline (intrahepatic triglyceride (IHTG)
content <5%), 1H-MRS was repeated after an interval of 3–5 years
(median 47 months). All cases had an anthropometric and bio-
chemical assessment for the features of metabolic syndrome,Journal of Hepatology 20
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sured by transient elastography. The incidence of fatty liver (78
new cases with IHTG >5%) was set at 3.4% per year, after exclu-
sion of two cases with excessive alcohol intake, with 20% of
new cases in the range of moderate-severe steatosis and only
one patient with liver stiffness indicative of advanced ﬁbrosis.
The presence of metabolic syndrome at baseline was the stron-
gest predictor of incident steatosis, which was also associated
with incident obesity, incident metabolic syndrome, and no
remission of impaired glucose tolerance.
In general, these data were largely expected, but the details of
the study open a number of important questions for future
research. In individual cases with incident fatty liver, IHTG
increased from values below 5% to values ranging up to 35%,
and more than doubled in 20% of cases. We know that changes
in MRS-determined IHTG may rapidly occur in response to die-
tary intake [12] and weight [13] modiﬁcations. Although a linear
trend was observed between baseline and follow-up IHTG levels,
incident fatty liver did not result merely from modest ﬂuctua-
tions around the cut-off of 5%, but in selected cases a dramatic
increase in IHTG levels occurred. Whether this is due to large
modiﬁcations in body weight/waist circumference or in the
habitual dietary intake/physical activity cannot be determined.
Metabolic syndrome was deﬁned according to the speciﬁc cri-
teria dictated for the Southeast Asian population by the Interna-
tional Diabetes Federation, using the cut-off point of waist
circumferenceP90 cm for males andP80 for females. The prob-
ability to develop incident fatty liver was related to both baseline
values and changes in waist circumference, but on average no
systematic differences in anthropometric parameters were
observed between baseline and follow-up measurements. In a
follow-up study of a Japanese cohort with previously elevated
liver enzymes – assumed as markers for NAFLD – maintaining
weight control after weight loss and habitual exercising were
predictive of long-term remission from NAFLD [14]. However, a
body weight within normal limits does not provide any guaran-
tee of keeping free of NAFLD [11]. Incident fatty liver developed
in 8% of cases with a BMI within the ethnic-speciﬁc cut-off of
23 kg/m2 both at baseline and at follow-up, as well as in a small
proportion of cases who moved their BMI from the overweight or
obese range to normal weight. This conﬁrms that factors inde-
pendent from anthropometric changes may be operative in
selected cases.15 vol. 62 j 15–17
Table 1. Studies on incident NAFLD in different populations.
Author, year 
[Ref.]
Study population Age; length of 
follow-up
Method of 
assessment
Estimated incidence Results
Hamaguchi, 
2005 [3]
704/3147 healthy 
Japanese cases 
with/without NAFLD 
Mean, 47.4 
(range, 21-80); 
F-U, 1.2 years
Ultrasounds 8.6%/years; FL 
resolution in 14.2%/
year
NAFLD more likely to develop – and 
less likely to regress – in subjects 
with the metabolic syndrome
Bruno, 
2005 [4]
5408 women after 
hysterectomy (Italian 
tamoxifene trial), 
with normal ALT
Median, 51; 
F-U, 5 years
ALT (+US 
when ALT 
elevated), ± 
liver biopsy
52 cases developed 
high ALT; 0.4/100 
women-year
Moderately higher incidence in 
women on tamoxifene, particularly in 
the presence of overweight/obesity 
Suzuki, 
2005 [5]
529 subjects free of 
previous liver injury 
(normal ALT)
Mean, 35; 
F-U, 5 years
ALT 31/1000 person-
years
Male sex, old age, high BMI, 
hypertension, and low HDL-
cholesterol associated with the risk 
of high ALT in subjects <40 years. 
In subjects >40, only IGT was a risk 
factor
Bedogni, 
2007 [6]
Members of the 
Dionysos cohort with 
SLD (307/134 
with/without fatty liver) 
Range, 12-65; 
F-U, 8.5 years
Ultrasounds 18.5/1000 person-
year
Incident fatty liver associated with 
alcohol. No systematic evaluation of 
incident NAFLD
Tsuneto, 
2010 [7]
1635 Nagasaki atomic 
bomb survivors, 
without fatty liver 
Mean, 63.1; 
F-U, 11.6 years
Ultrasounds 19.9/1000 person-
years (men, 22.3; 
women, 18.6) 
Incident fatty liver associated with 
obesity, hypertension and high TG.
Zelber-Sagi, 
2012 [8]
213 subjects (66/147 
with/without NAFLD)
Mean, 51.2;
F-U, 7 years
Ultrasounds 19.0% (2.7%/year); 
FL resolution in 
36.4% (5.2%/year)
Incident fatty liver associated with 
weight gain and baseline insulin 
resistance (HOMA). NAFLD 
remission associated with weight loss
Xu,
2013 [9]
5562 non-obese (BMI 
<25 kg/m2) NAFLD
Mean, 43.0; 
F-U, 5 years
Ultrasounds 8.9% Age, gender, BMI, WC, TG, HDL-
cholesterol, uric acid, hemoglobin, 
and platelet count independently 
associated with NAFLD development 
Sung,
2014 [10]
11,448 normotensive 
subjects (2959/8489 
with/without NAFLD)
Mean age, 40.6; 
F-U, 5 years
Ultrasounds 16.7% (3.3%/year); 
FL resolution in 
23.1% (4.6%/year)
Incident fatty liver associated with an 
increased risk of hypertension
Wong, 
2014 [11]
565 subjects without 
NAFLD (IHTG <5%) 
Mean, 48; median 
F-U, 47 months
1H-NMR-
spectroscopy
3.4%/year Incidence associated with age, 
increasing WC and TG, decreasing 
HDL-cholesterol. ALT significantly 
increased in subjects who develop 
NAFLD 
ALT, alanine aminotransferase; FL, fatty liver; F-U, follow-up; HDL, high density lipoprotein; HOMA, homeostasis model assessment; NMR, nuclear magnetic resonance;
SLD, suspected liver disease (high liver enzymes, high mean corpuscular volume, low platelet count); TG, triglycerides; US, ultrasonography; WC, waist circumference.
EditorialConsiderable attention should be paid to NAFLD development
in the absence of obesity, i.e., the improperly called ‘lean’ NAFLD
(more properly, ‘‘normal weight’’ NAFLD). Within the cohort of
the National Health and Nutrition Examination Survey III
(NHANES III), Younossi et al. identiﬁed 2492 individuals (18.8%)
with moderate-to-severe NAFLD at ultrasonography [15]. The
prevalence was as high as 27.7% in overweight/obese subjects,
signiﬁcantly higher than the 7.4% observed in subjects with nor-
mal BMI (<25 kg/m2). Multivariate analysis showed that ‘lean’
NAFLD was independently associated with diabetes, when com-
pared to lean controls, and with younger age, female sex, insulin
resistance and hypercholesterolemia, when compared with over-
weight/obese NAFLD patients. The authors conclude that ‘lean’
NAFLD individuals constitute a subgroup of patients relatively
free from the components of metabolic syndrome, usually associ-
ated with NAFLD. Similar data were reported in a tertiary care
liver unit [16], where ‘lean’ NAFLD had a reduced likelihood of
being associated with the components of metabolic syndrome,
but subjects were nonetheless insulin resistant when compared
to healthy controls. This intrinsic defect was conﬁrmed in a
cohort of subjects with biopsy-proven NAFLD, free of diabetes16 Journal of Hepatology 20and obesity, where insulin resistance was maintained, and the
metabolic pattern was similar to that observed in obesity, with
adipose tissue playing an important role [17].
The key question is whether ‘lean’ NAFLD carries the same risk
of progression as the fatty liver of obesity. Several cross sectional
analyses found that the presence of obesity or type 2 diabetes is a
risk factor for NAFLD severity. Unexpectedly, an international
study, involving several tertiary liver units, published so far only
in abstract form, reported a more severe prognosis in ‘lean’
biopsy-proven NAFLD compared with overweight or obese sub-
jects [18]. Of 1090 NAFLD cases (mean age, 46), only 125
(11.5%) were classiﬁed as ‘lean’ (BMI <25 kg/m2) at ﬁrst diagno-
sis; they were characterized by a lower prevalence of diabetes,
hypertension, hypertriglyceridemia, low-HDL cholesterol, central
obesity and metabolic syndrome, as well as more frequently nor-
mal liver enzymes and a lower prevalence or severity of insulin
resistance. At histology, ‘lean’ NAFLD had a lower grade/stage of
steatosis and ﬁbrosis, but more severe lobular inﬂammation. In
a cohort of 483 cases, ﬁrst observed before 2005, ‘lean’ vs. ‘non-
lean’ NAFLD patients were compared in a cumulative overall sur-
vival analysis over a mean follow-up period of over 11 years.15 vol. 62 j 15–17
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Mortality was signiﬁcantly higher in ‘lean’ patients and the Cox
model identiﬁed ‘lean’ NAFLD (HR 11.8; 95% CI 2.8–50.1;
p = 0.001) and age as prognostic factors, after adjustment for
confounders.
We also know that subjects with massive fatty liver, related to
defects in lipoprotein metabolism, are relatively free of hepatic
necroinﬂammation, ﬁbrosis and disease progression. Why should
subjects with ‘lean’ NAFLD be at higher risk of mortality? In the
study by Wong et al. [11], the presence of the common variant
in the patatin-like phospholipase-3 gene (PNPLA3), known to con-
fer susceptibility to NAFLD [19], did not provide any relevant clue
for incident NAFLD, but other variants in different loci may be
involved in individual cases.
The ﬁnal question is how to manage subjects diagnosed with
NAFLD, given the very large number of cases, the difﬁculty in pre-
dicting evolution, and the slow progression and long duration of
disease. If the poorer prognosis of ‘lean’ NAFLD was conﬁrmed,
this cohort might deserve more systematic surveillance and
treatment. Although several new drugs are under investigations
for more progressive disease, weight loss remains the back-
ground therapy in all cases with overweight/obesity. The results
are generally poor, but a 7% weight loss signiﬁcantly modiﬁes
liver histology. In ‘lean’ NAFLD patients, where weight loss can-
not be a reasonable target of therapy, a psychological program
to support patients towards habitual physical activity might also
be indicated. There is evidence that habitual physical activity is
approximately as effective as a standard weight loss program
on liver enzymes and cardiovascular ﬁtness [20]. The study by
Wong et al. [11] provides the framework for future intervention;
the evidence that incidence and remission are not solely related
to body weight changes must dictate tailored treatment in indi-
vidual patients.Conﬂict of interest
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